Rx Medicare

ROXRO announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead investigational prescription drug candidate, ROX-888, for the management of acute moderate to severe pain.

Read More…

Related Posts

• QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain
• FDA Approves EMBEDA(TM) For Management Of Moderate To Severe Chronic Pain
• NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain
• Nutra Pharma Announces Online Availability Of Cobroxin For The Treatment Of Moderate To Severe Chronic Pain
• 95% Of Patients In Pain Are Still In Moderate To Severe Chronic Pain Despite One Year Of Treatment
• XenaCare Holdings Announces National Print Advertising Campaign For Cobroxin, A Treatment For Moderate To Severe (Stage 2) Pain
• China Aoxing Pharmaceutical Company Announces Submission Of NDA Of Its Leading Narcotic Drug For The Treatment Of Acute Moderate To Severe Cough
• Nutra Pharma Announces Launch Of Cobroxin, An Over-the-Counter (OTC) Treatment For Stage 2 (Moderate To Severe) Chronic Pain
• Repros Thera. Announces That Proellex Significantly Reduced Pain In A U.S. Phase 2 Clinical Trial In Women With Moderate To Severe Endometriosis
• Acute Study Demonstrates Safety Of Vertos Medical’s Mild(R) Procedure; Findings Appear In Pain Physician Journal
• New Pain Management Approaches Reduce Pain, Speed Recovery For Knee Or Hip Replacement
• FDA Approves Morphine Sulfate Oral Solution For Relief Of Acute And Chronic Pain
• Fear Of Prescription Drug Abuse Affects Pain Management
• Pain management failing as fears of prescription drug abuse rise
• Ultrasound-guided cortisone injections may help treat severe hip pain

Tags: accepts, acute, management, moderate, pain, review, roxro, severe

This entry was posted on Saturday, February 7th, 2009 at 11:02 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.